STOCK TITAN

Autolus Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Autolus Therapeutics plc (Nasdaq: AUTL) announced that CEO Dr. Christian Itin will present at the virtual H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The event will feature one-on-one meetings with participants. A live audio webcast of the presentation will be available on Autolus’ investor relations page starting March 9 at 7:00 a.m. EST, with an archived replay accessible for 90 days. Autolus is focused on developing next-generation programmed T cell therapies aimed at treating various cancers.

Positive
  • None.
Negative
  • None.

LONDON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. Christian Itin, chairman and chief executive officer, will present at the H.C. Wainwright Global Life Sciences Conference being held virtually from March 9-10, 2021. The company will also host one-on-one meetings with attendees.

A live audio webcast of the presentation will be available on-demand on the investor relations section of Autolus’ website at events starting March 9 at 7.00 a.m. EST. An archived replay will be available on the company’s website for a period of 90 days after the conference.

About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit www.autolus.com.

Contact:

Lucinda Crabtree, PhD
Vice President, Investor Relations and Corporate Communications
+44 (0) 7587 372 619
l.crabtree@autolus.com

Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com

Susan A. Noonan
S.A. Noonan Communications
+1-212-966-3650
susan@sanoonan.com


FAQ

When will Autolus Therapeutics present at the H.C. Wainwright Conference?

Autolus Therapeutics will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021.

Who will present for Autolus at the conference?

Dr. Christian Itin, the CEO, will present for Autolus Therapeutics at the conference.

Is there a webcast for Autolus Therapeutics' presentation?

Yes, a live audio webcast of the presentation will be available on Autolus' investor relations page starting March 9 at 7:00 a.m. EST.

How long will the presentation replay be available?

The archived replay of Autolus Therapeutics' presentation will be available for 90 days after the conference.

What is the focus of Autolus Therapeutics?

Autolus Therapeutics is focused on developing next-generation programmed T cell therapies for the treatment of cancer.

Autolus Therapeutics plc American Depositary Share

NASDAQ:AUTL

AUTL Rankings

AUTL Latest News

AUTL Stock Data

798.37M
213.36M
18.09%
76.21%
2.7%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
LONDON